INSIDER
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Alerts on Telegram

Congress trades and big insider sales, sent the day they're filed. Free.

Open in Telegram
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

Robinhood Chain…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyTelegram alerts
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Alerts on Telegram

Congress trades and big insider sales, sent the day they're filed. Free.

Open in Telegram
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyTelegram alerts
03 · Corporate insiders

Form 4 filings

Officers, directors and 10% owners must report trades within two business days on SEC Form 4. INSIDER parses each filing's XML from EDGAR. By default only discretionary open-market purchases and sales are shown; grants, option exercises and tax withholding are one click away.

Form 4 transactions

Cluster activity · 60d

Most active filers

Companies with the most Form 4 filings
Data sources
SEC Form 41h ago
House PTR1h ago
SEC 13F1h ago
Robinhood Chain1h ago

Most active filers · 30d

  1. 01Kurtz George0B / 215S215 trades$52.62M
  2. 02FWFogarty Patrick W0B / 206S206 trades$1.10M
  3. 03SPSaba Capital Management, L.P.65B / 19S · 11 late84 trades$21.64M
  4. 04NYNissan Yitzhak82B / 0S · 79 late82 trades$2.61M
  5. 05ATAdair Kathleen Theresa52B / 0S · 52 late52 trades$18K
  6. 06AJAllaire Jeremy0B / 50S50 trades$4.26M
  7. 07Wilhelmsen Arne Alexander0B / 47S47 trades$241.96M
  8. 08SJSheena Jonathan0B / 45S45 trades$3.01M
  9. 09SISarowitz Steven I2B / 34S36 trades$22.46M
  10. 10SLSpeiser Michael L0B / 35S35 trades$14.00M

Cluster activity · 60d

  1. BUYTSMTAIWAN SEMICONDUCTOR MANUFACTURING CO LTDNov 5 – Nov 1732 insiders$917K
  2. SELLDRDDRDGOLD LTDOct 27 – Oct 2710 insiders$1.23M
  3. BUYMTDRMatador Resources CoNov 5 – Nov 179 insiders$893K
  4. SELLMSIMotorola Solutions, Inc.Nov 6 – Nov 168 insiders$42.58M
  5. SELLFFIVF5, INC.Nov 3 – Nov 58 insiders$8.37M
  6. SELLIBEXIBEX LtdNov 9 – Nov 167 insiders$3.36M
  7. SELLMGNIMAGNITE, INC.Nov 5 – Nov 127 insiders$2.27M
  8. SELLSYMSymbotic Inc.Oct 26 – Nov 27 insiders$1.98M

Form 4 transactions

72,770 records
Side
allbuysell
Score
any≥ 30≥ 50≥ 70
Sort
Newest disclosedNewest executedInsider ScoreValue
Include
grants & admin
ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
9
JN
Jones NonaDirector
GLOOGloo Holdings, Inc.
Grant or award
A—
7,500 sh
Dec 26, 2025Dec 29, 2025
Page 1572 of 1820
← PrevNext →
traded Dec 26, 2025
+3d
SEC Form 4

Evidence

9
GR
Gruenewald RobertDirector
GLOOGloo Holdings, Inc.
Grant or award
A—
138.9K sh
Dec 26, 2025Dec 29, 2025
traded Dec 26, 2025
+3dSEC Form 4

Evidence

8
BR
Bentley Sheldon Richard10% Owner, Founder
CSAICLOUDASTRUCTURE, INC.
Open-market sale · 10b5-1 plan
SELL$26K
25.0K sh
Dec 23, 2025Dec 29, 2025
traded Dec 23, 2025
+6dSEC Form 4

Evidence

8
BR
Bentley Sheldon Richard10% Owner, Founder
CSAICLOUDASTRUCTURE, INC.
Open-market sale · 10b5-1 plan
SELL$26K
25.0K sh
Dec 24, 2025Dec 29, 2025
traded Dec 24, 2025
+5dSEC Form 4

Evidence

7
AA
Ashish AroraDirector, Chief Executive Officer, 10% Owner
CRCTCricut, Inc.
Open-market sale · 10b5-1 plan
SELL$104K
20.8K sh
Dec 23, 2025Dec 29, 2025
traded Dec 23, 2025
+6dSEC Form 4

Evidence

7
AA
Ashish AroraDirector, Chief Executive Officer, 10% Owner
CRCTCricut, Inc.
Open-market sale · 10b5-1 plan
SELL$107K
20.8K sh
Dec 22, 2025Dec 29, 2025
traded Dec 22, 2025
+7dSEC Form 4

Evidence

7
AA
Ashish AroraDirector, Chief Executive Officer, 10% Owner
CRCTCricut, Inc.
Open-market sale · 10b5-1 plan
SELL$103K
20.8K sh
Dec 24, 2025Dec 29, 2025
traded Dec 24, 2025
+5dSEC Form 4

Evidence

5
SS
Skates SpenserDirector, Chief Executive Officer, 10% Owner
AMPLAmplitude, Inc.
Derivative conversion · 10b5-1 plan
C—
42.7K sh
Dec 24, 2025Dec 29, 2025
traded Dec 24, 2025
+5dSEC Form 4

Evidence

5
RE
Rote William E.Chief Research Officer
TVTXTravere Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
60.0K sh
Dec 24, 2025Dec 29, 2025
traded Dec 24, 2025
+5dSEC Form 4

Evidence

5
LF
Lo FrancisChief People Officer
ADPTAdaptive Biotechnologies Corp
Option exercise · 10b5-1 plan
M$4,389
1,100 sh
Dec 22, 2025Dec 29, 2025
traded Dec 22, 2025
+7dSEC Form 4

Evidence

5
LF
Lo FrancisChief People Officer
ADPTAdaptive Biotechnologies Corp
Option exercise · 10b5-1 plan
M—
2,194 sh
Dec 22, 2025Dec 29, 2025
traded Dec 22, 2025
+7dSEC Form 4

Evidence

5
LF
Lo FrancisChief People Officer
ADPTAdaptive Biotechnologies Corp
Option exercise · 10b5-1 plan
M—
1,100 sh
Dec 22, 2025Dec 29, 2025
traded Dec 22, 2025
+7dSEC Form 4

Evidence

5
LF
Lo FrancisChief People Officer
ADPTAdaptive Biotechnologies Corp
Option exercise · 10b5-1 plan
M$19K
2,194 sh
Dec 22, 2025Dec 29, 2025
traded Dec 22, 2025
+7dSEC Form 4

Evidence

5
LF
Lo FrancisChief People Officer
ADPTAdaptive Biotechnologies Corp
Option exercise · 10b5-1 plan
M$8,580
1,100 sh
Dec 22, 2025Dec 29, 2025
traded Dec 22, 2025
+7dSEC Form 4

Evidence

5
LF
Lo FrancisChief People Officer
ADPTAdaptive Biotechnologies Corp
Option exercise · 10b5-1 plan
M—
1,100 sh
Dec 22, 2025Dec 29, 2025
traded Dec 22, 2025
+7dSEC Form 4

Evidence

5
FA
Flees Lori AnnDirector, President & CEO
VVVVALVOLINE INC
Grant or award
A$1,775
59 sh
Dec 26, 2025Dec 29, 2025
traded Dec 26, 2025
+3dSEC Form 4

Evidence

4
Dines DanielDirector, CEO and Chairman, 10% Owner
PATHUiPath, Inc.
Open-market sale · 10b5-1 plan
SELL$740K
45.0K sh
Dec 29, 2025Dec 29, 2025
traded Dec 29, 2025
+0dSEC Form 4

Evidence

4
Dines DanielDirector, CEO and Chairman, 10% Owner
PATHUiPath, Inc.
Open-market sale · 10b5-1 plan
SELL$761K
45.0K sh
Dec 26, 2025Dec 29, 2025
traded Dec 26, 2025
+3dSEC Form 4

Evidence

4
WC
Wren ChrisVP of Operations
PLNHPlanet 13 Holdings Inc.
Open-market sale · 10b5-1 plan
SELL$6,849
30.0K sh
Dec 24, 2025Dec 29, 2025
traded Dec 24, 2025
+5dSEC Form 4

Evidence

4
RM
Rizik MatthewDirector
RKTRocket Companies, Inc.
Open-market sale · 10b5-1 plan
SELL$49K
2,500 sh
Dec 24, 2025Dec 29, 2025
traded Dec 24, 2025
+5dSEC Form 4

Evidence

4
RM
Rizik MatthewDirector
RKTRocket Companies, Inc.
Open-market sale · 10b5-1 plan
SELL$47K
2,500 sh
Dec 23, 2025Dec 29, 2025
traded Dec 23, 2025
+6dSEC Form 4

Evidence

4
BS
Beatty Jonathan SMD, Head of Advisor Services
SCHWSCHWAB CHARLES CORP
Option exercise · 10b5-1 plan
M$93K
2,000 sh
Dec 23, 2025Dec 29, 2025
traded Dec 23, 2025
+6dSEC Form 4

Evidence

3
WL
Wu LeiDirector, Chief Executive Officer, 10% Owner
GCTGigaCloud Technology Inc
Derivative conversion · 10b5-1 plan
C—
800.0K sh
Dec 26, 2025Dec 29, 2025
traded Dec 26, 2025
+3dSEC Form 4

Evidence

2
SB
Slowe Christopher BrianChief Technology Officer
RDDTReddit, Inc.
Derivative conversion · 10b5-1 plan
C—
12.0K sh
Dec 22, 2025Dec 29, 2025
traded Dec 22, 2025
+7dSEC Form 4

Evidence

1
SS
Skates SpenserDirector, Chief Executive Officer, 10% Owner
AMPLAmplitude, Inc.
Derivative conversion · 10b5-1 plan
C—
42.7K sh
Dec 24, 2025Dec 29, 2025
traded Dec 24, 2025
+5dSEC Form 4

Evidence

1
BS
Beatty Jonathan SMD, Head of Advisor Services
SCHWSCHWAB CHARLES CORP
Option exercise · 10b5-1 plan
M—
2,000 sh
Dec 23, 2025Dec 29, 2025
traded Dec 23, 2025
+6dSEC Form 4

Evidence

0
SB
Slowe Christopher BrianChief Technology Officer
RDDTReddit, Inc.
Option exercise · 10b5-1 plan
M—
12.0K sh
Dec 22, 2025Dec 29, 2025
traded Dec 22, 2025
+7dSEC Form 4

Evidence

0
VM
Venturo Brian MDirector, Chief Strategy Officer
CRWVCoreWeave, Inc.
Derivative conversion · 10b5-1 plan
C—
281.3K sh
Dec 24, 2025Dec 29, 2025
traded Dec 24, 2025
+5dSEC Form 4

Evidence

0
VM
Venturo Brian MDirector, Chief Strategy Officer
CRWVCoreWeave, Inc.
Derivative conversion · 10b5-1 plan
C—
281.3K sh
Dec 24, 2025Dec 29, 2025
traded Dec 24, 2025
+5dSEC Form 4

Evidence

0
RM
Rizik MatthewDirector
RKTRocket Companies, Inc.
Open-market sale · 10b5-1 plan
SELL$48K
2,500 sh
Dec 26, 2025Dec 29, 2025
traded Dec 26, 2025
+3dSEC Form 4

Evidence

0
SB
Slowe Christopher BrianChief Technology Officer
RDDTReddit, Inc.
Derivative conversion · 10b5-1 plan
C—
12.0K sh
Dec 22, 2025Dec 29, 2025
traded Dec 22, 2025
+7dSEC Form 4

Evidence

54
LY
Louie Ngar YeeDirector
MAIAMAIA Biotechnology, Inc.
Open-market purchase
BUY$111K
81.7K sh
Dec 22, 2025Dec 23, 2025
traded Dec 22, 2025
+1dSEC Form 4

Evidence

54
CM
Chaouki Steven MDirector
MAIAMAIA Biotechnology, Inc.
Open-market purchase
BUY$56K
40.8K sh
Dec 22, 2025Dec 23, 2025
traded Dec 22, 2025
+1dSEC Form 4

Evidence

51
FF
Flannery FionaDirector
GFNEW GERMANY FUND INC
Open-market purchase
BUY$10K
872 sh
Dec 15, 2025Dec 23, 2025
traded Dec 15, 2025
+8dSEC Form 4

Evidence

48
ZN
Zojwalla NaseemChief Medical Officer
OLMAOlema Pharmaceuticals, Inc.
Open-market sale
SELL$2.80M
100.0K sh
Dec 22, 2025Dec 23, 2025
traded Dec 22, 2025
+1dSEC Form 4

Evidence

48
ZN
Zojwalla NaseemChief Medical Officer
OLMAOlema Pharmaceuticals, Inc.
Open-market sale
SELL$1.60M
57.1K sh
Dec 19, 2025Dec 23, 2025
traded Dec 19, 2025
+4dSEC Form 4

Evidence

48
ZN
Zojwalla NaseemChief Medical Officer
OLMAOlema Pharmaceuticals, Inc.
Open-market sale
SELL$2.75M
99.5K sh
Dec 23, 2025Dec 23, 2025
traded Dec 23, 2025
+0dSEC Form 4

Evidence

47
CM
Chaouki Steven MDirector
MAIAMAIA Biotechnology, Inc.
Open-market purchase
BUY$50K
40.8K sh
Dec 22, 2025Dec 23, 2025
traded Dec 22, 2025
+1dSEC Form 4

Evidence

47
SS
Smith StanDirector
MAIAMAIA Biotechnology, Inc.
Open-market purchase
BUY$78K
57.2K sh
Dec 22, 2025Dec 23, 2025
traded Dec 22, 2025
+1dSEC Form 4

Evidence

46
LY
Louie Ngar YeeDirector
MAIAMAIA Biotechnology, Inc.
Open-market purchase
BUY$100K
81.7K sh
Dec 22, 2025Dec 23, 2025
traded Dec 22, 2025
+1dSEC Form 4

Evidence